Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal absorption, and non-compliance.
Major drivers of the IV iron drugs market are increase in incidence of iron deficiency, rise in chronic kidney disease patients undergoing dialysis, and surging diabetic population. Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology, noncompliance of oral therapy, and accurate, easy, and convenient access to IV iron dosages drive demand for intravenous iron drugs. However, complex approval process, stringent regulations, drug side effects, nutraceutical alternatives to prevent iron deficiency, and product price are likely to act as major restraints of the IV iron drugs market.
Market Analysis and Insights: Global Intraveno(IV) Iron Drugs Market
The global Intraveno(IV) Iron Drugs market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.
Global Intraveno(IV) Iron Drugs Scope and Market Size
The global Intraveno(IV) Iron Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Intraveno(IV) Iron Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Low Molecular Weight Iron Dextran
Ferric Gluconate
Iron Sucrose
Ferric Carboxyl Maltose
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
The Intraveno(IV) Iron Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Intraveno(IV) Iron Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Allergan
AMAG Pharmaceuticals
Galenica
Actavis
American Regent
Sanofi
Luitpold Pharmaceuticals
Fresenius Medical Care
Pharmacosmos
Vifor Pharma
Major drivers of the IV iron drugs market are increase in incidence of iron deficiency, rise in chronic kidney disease patients undergoing dialysis, and surging diabetic population. Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology, noncompliance of oral therapy, and accurate, easy, and convenient access to IV iron dosages drive demand for intravenous iron drugs. However, complex approval process, stringent regulations, drug side effects, nutraceutical alternatives to prevent iron deficiency, and product price are likely to act as major restraints of the IV iron drugs market.
Market Analysis and Insights: Global Intraveno(IV) Iron Drugs Market
The global Intraveno(IV) Iron Drugs market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.
Global Intraveno(IV) Iron Drugs Scope and Market Size
The global Intraveno(IV) Iron Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Intraveno(IV) Iron Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Low Molecular Weight Iron Dextran
Ferric Gluconate
Iron Sucrose
Ferric Carboxyl Maltose
Segment by Application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
The Intraveno(IV) Iron Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Intraveno(IV) Iron Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Allergan
AMAG Pharmaceuticals
Galenica
Actavis
American Regent
Sanofi
Luitpold Pharmaceuticals
Fresenius Medical Care
Pharmacosmos
Vifor Pharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
